Literature DB >> 31005624

Delayed presentation to a spine surgeon is the strongest predictor of poor postoperative outcome in patients surgically treated for symptomatic spinal metastases.

Floris R van Tol1, David Choi2, Helena M Verkooijen3, F Cumhur Oner4, Jorrit-Jan Verlaan4.   

Abstract

BACKGROUND CONTEXT: Symptoms associated with spinal metastases are often nonspecific and resemble noncancer-related symptoms. Therefore, patients with spinal metastases are at risk for delayed referral and treatment. Delayed presentation of symptomatic spinal metastases may lead to the development of neurological deficits, often followed by emergency surgery.
PURPOSE: The aim of this cohort study was to analyze the effect of delayed referral and treatment of spinal metastases on clinical outcome.
METHODS: We included all patients surgically treated for spinal metastases at our tertiary care center. Based on the (in)ability to undergo elective surgery, patients were identified as timely treated or delayed. Patient- and tumor-characteristics, surgical variables, and postoperative variables such as complication rate, the ability to return home and length of hospital stay were recorded and compared between the two groups.
RESULTS: Based on the urgency of treatment at admission, 206 patients were identified as timely treated and 98 as delayed. At baseline, the two groups did not differ significantly except for the extent of neurological symptoms. Timely treated patients underwent less invasive procedures (52.9% vs 13.3% percutaneous pedicle screw fixations), had less median blood loss (200cc vs 450cc), shorter median admission time (7 vs 13 days), lower complication rate (26.2% vs 48.0%) and higher chances of being discharged home immediately (82.6% vs 41.1%) compared with delayed patients. Using multivariate regression models these correlations remained present independent of tumor prognosis, preoperative mobility, and American Society of Anesthesiologists-score.
CONCLUSIONS: The delayed presentation of patients with spinal metastases to a spinal surgeon is strongly and independently associated with worse surgical and postoperative outcome parameters. Improvements in referral patterns could potentially lead to more scheduled care, negating the detrimental effects of delay. Crown
Copyright © 2019. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Delay; Early treatment; Emergency surgery; Patient outcome; Spinal metastases; Spine surgery

Year:  2019        PMID: 31005624     DOI: 10.1016/j.spinee.2019.04.011

Source DB:  PubMed          Journal:  Spine J        ISSN: 1529-9430            Impact factor:   4.166


  4 in total

Review 1.  [Intraoperative and late complications after spinal tumour resection and dorsoventral reconstruction].

Authors:  A Thomas; T Hollstein; S Zwingenberger; K-D Schaser; A C Disch
Journal:  Orthopade       Date:  2020-02       Impact factor: 1.087

2.  Multidisciplinary Approach to Patients With Metastatic Spinal Cord Compression: A Diagnostic Therapeutic Algorithm to Improve the Neurological Outcome.

Authors:  Rossella Rispoli; Chiara Reverberi; Giada Targato; Serena D'Agostini; Gianpiero Fasola; Marco Trovò; Mario Calci; Renato Fanin; Barbara Cappelletto
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

3.  Deep Learning Model for Classifying Metastatic Epidural Spinal Cord Compression on MRI.

Authors:  James Thomas Patrick Decourcy Hallinan; Lei Zhu; Wenqiao Zhang; Desmond Shi Wei Lim; Sangeetha Baskar; Xi Zhen Low; Kuan Yuen Yeong; Ee Chin Teo; Nesaretnam Barr Kumarakulasinghe; Qai Ven Yap; Yiong Huak Chan; Shuxun Lin; Jiong Hao Tan; Naresh Kumar; Balamurugan A Vellayappan; Beng Chin Ooi; Swee Tian Quek; Andrew Makmur
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

4.  Surgery in Acute Metastatic Spinal Cord Compression: Timing and Functional Outcome.

Authors:  Hanno S Meyer; Arthur Wagner; Alessandra Raufer; Ann-Kathrin Joerger; Jens Gempt; Bernhard Meyer
Journal:  Cancers (Basel)       Date:  2022-04-30       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.